Cargando…
Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis
BACKGROUND: Ulcerative colitis (UC) is a chronic, non-specific inflammatory bowel disease (IBD) with unknown etiology. The lack of specific clinical manifestations, standard diagnostic criteria, objective and accurate indicators to the severity of the disease and the efficacy of the treatment, often...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238601/ https://www.ncbi.nlm.nih.gov/pubmed/32477415 http://dx.doi.org/10.1186/s13223-020-00433-1 |
_version_ | 1783536565137440768 |
---|---|
author | Pang, Yanhua Ruan, Huijie Wu, Dongfang Lang, Yanfei Sun, Ke Xu, Cuiping |
author_facet | Pang, Yanhua Ruan, Huijie Wu, Dongfang Lang, Yanfei Sun, Ke Xu, Cuiping |
author_sort | Pang, Yanhua |
collection | PubMed |
description | BACKGROUND: Ulcerative colitis (UC) is a chronic, non-specific inflammatory bowel disease (IBD) with unknown etiology. The lack of specific clinical manifestations, standard diagnostic criteria, objective and accurate indicators to the severity of the disease and the efficacy of the treatment, often results in difficulties in diagnosis and timely treatment of UC. Therefore, there is a need to develop a clinically suitable serum biomarker assay with high specificity and sensitivity. OBJECTIVE AND METHODS: To explore the significance of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-saccharomyces cerevisiae antibodies (ASCA) in the diagnosis, differential diagnosis and treatment assessment in patients with ulcerative colitis (UC). Serum levels of ANCA-IgG, ASCA-IgA and ASCA-IgG were measured by an enzyme-linked immunosorbent assay (ELISA) in 105 UC patients, 52 non-UC patients and 100 healthy controls. RESULTS: (1) Both the ANCA-IgG level and its positive rate in UC patients were significantly higher than those in non-UC controls and healthy controls (p < 0.01). However, the levels of ASCA-IgA, ASCA-IgG and the positive rates in UC patients had no statistical differences when compared with those in non-UC controls or healthy controls (p > 0.05). (2) The sensitivity of ANCA(+) and ANCA(+)/ASCA(−) in detecting UC patients was 61.90% and 55.24%, respectively, whereas the specificity was 91.45% and 94.08%, respectively. The sensitivity of ASCA(+) and ASCA(+)/ANCA(−) in non-UC disease controls was 5.33% and 3.85%, respectively, and specificity was 83.9% and 88.78%, respectively. (3) When UC patients were grouped into mild, moderate or severe subtypes, the ANCA-IgG levels were correlated with the severity of UC, and the differences of the ANCA-IgG levels were statistically different among the three subtypes (p < 0.05). There was no correlation between the levels of ANCA-IgG and the disease locations of UC. CONCLUSIONS: (1) Serum levels of ANCA may be useful in the diagnosis of UC. (2) Dynamic quantitation of ANCA-IgG levels may be helpful in determining the severity of UC and therefore, may guide treatment of UC. |
format | Online Article Text |
id | pubmed-7238601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72386012020-05-29 Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis Pang, Yanhua Ruan, Huijie Wu, Dongfang Lang, Yanfei Sun, Ke Xu, Cuiping Allergy Asthma Clin Immunol Research BACKGROUND: Ulcerative colitis (UC) is a chronic, non-specific inflammatory bowel disease (IBD) with unknown etiology. The lack of specific clinical manifestations, standard diagnostic criteria, objective and accurate indicators to the severity of the disease and the efficacy of the treatment, often results in difficulties in diagnosis and timely treatment of UC. Therefore, there is a need to develop a clinically suitable serum biomarker assay with high specificity and sensitivity. OBJECTIVE AND METHODS: To explore the significance of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-saccharomyces cerevisiae antibodies (ASCA) in the diagnosis, differential diagnosis and treatment assessment in patients with ulcerative colitis (UC). Serum levels of ANCA-IgG, ASCA-IgA and ASCA-IgG were measured by an enzyme-linked immunosorbent assay (ELISA) in 105 UC patients, 52 non-UC patients and 100 healthy controls. RESULTS: (1) Both the ANCA-IgG level and its positive rate in UC patients were significantly higher than those in non-UC controls and healthy controls (p < 0.01). However, the levels of ASCA-IgA, ASCA-IgG and the positive rates in UC patients had no statistical differences when compared with those in non-UC controls or healthy controls (p > 0.05). (2) The sensitivity of ANCA(+) and ANCA(+)/ASCA(−) in detecting UC patients was 61.90% and 55.24%, respectively, whereas the specificity was 91.45% and 94.08%, respectively. The sensitivity of ASCA(+) and ASCA(+)/ANCA(−) in non-UC disease controls was 5.33% and 3.85%, respectively, and specificity was 83.9% and 88.78%, respectively. (3) When UC patients were grouped into mild, moderate or severe subtypes, the ANCA-IgG levels were correlated with the severity of UC, and the differences of the ANCA-IgG levels were statistically different among the three subtypes (p < 0.05). There was no correlation between the levels of ANCA-IgG and the disease locations of UC. CONCLUSIONS: (1) Serum levels of ANCA may be useful in the diagnosis of UC. (2) Dynamic quantitation of ANCA-IgG levels may be helpful in determining the severity of UC and therefore, may guide treatment of UC. BioMed Central 2020-05-20 /pmc/articles/PMC7238601/ /pubmed/32477415 http://dx.doi.org/10.1186/s13223-020-00433-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Pang, Yanhua Ruan, Huijie Wu, Dongfang Lang, Yanfei Sun, Ke Xu, Cuiping Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis |
title | Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis |
title_full | Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis |
title_fullStr | Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis |
title_full_unstemmed | Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis |
title_short | Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis |
title_sort | assessment of clinical activity and severity using serum anca and asca antibodies in patients with ulcerative colitis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238601/ https://www.ncbi.nlm.nih.gov/pubmed/32477415 http://dx.doi.org/10.1186/s13223-020-00433-1 |
work_keys_str_mv | AT pangyanhua assessmentofclinicalactivityandseverityusingserumancaandascaantibodiesinpatientswithulcerativecolitis AT ruanhuijie assessmentofclinicalactivityandseverityusingserumancaandascaantibodiesinpatientswithulcerativecolitis AT wudongfang assessmentofclinicalactivityandseverityusingserumancaandascaantibodiesinpatientswithulcerativecolitis AT langyanfei assessmentofclinicalactivityandseverityusingserumancaandascaantibodiesinpatientswithulcerativecolitis AT sunke assessmentofclinicalactivityandseverityusingserumancaandascaantibodiesinpatientswithulcerativecolitis AT xucuiping assessmentofclinicalactivityandseverityusingserumancaandascaantibodiesinpatientswithulcerativecolitis |